ESPR

2.57

0.00% 0.00

Dopo l'orario di chiusura: 2.57

Esperion Therapeutics Inc (ESPR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ESPR Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$2.57

Aprire:

$2.52

Volume 24 ore:

6.40M

Relative Volume:

1.70

Capitalizzazione di mercato:

$486.91M

Reddito:

$116.33M

Utile/perdita netta:

$-209.25M

Rapporto P/E:

-0.9113

EPS:

-2.82

Flusso di cassa netto:

$-135.49M

1 W Prestazione:

+6.64%

1M Prestazione:

+22.38%

6M Prestazione:

+20.66%

1 anno Prestazione:

+105.60%

Intervallo 1D:

$2.5106

$2.61

Intervallo di 1 settimana:

$2.305

$2.615

Portata 52W:

$1.1601

$3.40

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Nome

Esperion Therapeutics Inc

Settore

Healthcare (1182)

Industria

Drug Manufacturers - Specialty & Generic (86)

Telefono

734-887-3903

Indirizzo

3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI

Dipendente

240

Cinguettio

@esperioninc

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

ESPR's Discussions on Twitter

Confronta ESPR con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ESPR Esperion Therapeutics Inc	2.57	486.91M	116.33M	-209.25M	-135.49M	-2.82
ZTS Zoetis Inc	175.70	79.27B	9.15B	2.43B	2.31B	4.92
HLN Haleon Plc Adr	9.59	43.23B	14.26B	1.55B	0	0.3327
TAK Takeda Pharmaceutical Co Adr	13.44	42.56B	30.27B	1.93B	3.45B	0.444
TEVA Teva Pharmaceutical Industries Ltd Adr	16.59	18.79B	16.77B	-959.00M	1.37B	-2.00
VTRS Viatris Inc	13.08	15.61B	15.05B	-883.30M	1.89B	1.53

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-06-20	Downgrade	BofA Securities	Neutral → Underperform
2024-01-03	Downgrade	BofA Securities	Buy → Neutral
2023-11-20	Ripresa	JP Morgan	Neutral
2023-08-01	Aggiornamento	Northland Capital	Under Perform → Market Perform
2023-06-15	Aggiornamento	BofA Securities	Underperform → Buy
2023-03-16	Downgrade	BofA Securities	Neutral → Underperform
2023-03-16	Downgrade	Northland Capital	Market Perform → Under Perform
2023-03-07	Aggiornamento	Credit Suisse	Underperform → Neutral
2023-02-27	Ripresa	BofA Securities	Neutral
2023-02-24	Aggiornamento	Jefferies	Hold → Buy
2023-02-03	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2022-08-03	Downgrade	Credit Suisse	Neutral → Underperform
2022-05-05	Aggiornamento	JP Morgan	Underweight → Neutral
2022-03-10	Iniziato	H.C. Wainwright	Buy
2021-10-19	Downgrade	Credit Suisse	Outperform → Neutral
2021-10-14	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2021-05-05	Downgrade	Stifel	Buy → Hold
2021-04-26	Ripresa	Credit Suisse	Outperform
2021-03-11	Iniziato	Morgan Stanley	Equal-Weight
2021-02-12	Downgrade	Jefferies	Buy → Hold
2021-02-09	Downgrade	Goldman	Neutral → Sell
2021-01-15	Downgrade	BofA Securities	Buy → Neutral
2020-11-10	Aggiornamento	Credit Suisse	Neutral → Outperform
2020-09-29	Ripresa	JP Morgan	Underweight
2020-08-11	Downgrade	Credit Suisse	Outperform → Neutral
2020-04-01	Ripresa	BofA/Merrill	Buy
2020-03-17	Aggiornamento	Citigroup	Neutral → Buy
2020-02-24	Downgrade	Northland Capital	Outperform → Market Perform
2020-02-14	Downgrade	Citigroup	Buy → Neutral
2019-09-16	Aggiornamento	Goldman	Sell → Neutral
2019-05-29	Downgrade	Goldman	Neutral → Sell
2019-05-06	Aggiornamento	BofA/Merrill	Underperform → Neutral
2019-04-26	Aggiornamento	Goldman	Sell → Neutral
2019-03-13	Aggiornamento	JP Morgan	Underweight → Neutral
2019-01-07	Reiterato	Needham	Strong Buy
2018-12-13	Iniziato	Goldman	Sell
2018-10-29	Aggiornamento	Northland Capital	Market Perform → Outperform
2018-10-16	Iniziato	BTIG Research	Buy
2018-08-17	Aggiornamento	Citigroup	Neutral → Buy
2018-07-11	Downgrade	Northland Capital	Outperform → Market Perform
2018-05-03	Downgrade	JP Morgan	Neutral → Underweight
2018-05-02	Downgrade	BofA/Merrill	Buy → Underperform

Mostra tutto

Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie

Nov 26, 2024

Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia - GlobeNewswire

Nov 26, 2024

Esperion's Cholesterol Drug Shows 25% LDL Reduction in Japan Trial, Advances to NDA | ESPR Stock News - StockTitan

Nov 26, 2024

Nov 21, 2024

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire

Nov 21, 2024

Esperion to Present at Piper Sandler Healthcare Conference, Showcases Cardiovascular Pipeline | ESPR Stock News - StockTitan

Nov 21, 2024

Esperion's chief commercial officer sells shares worth $426 By Investing.com - Investing.com South Africa

Nov 21, 2024

Nov 20, 2024

Esperion's chief commercial officer sells shares worth $426 - Investing.com

Nov 20, 2024

Nov 19, 2024

Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from HC Wainwright - MarketBeat

Nov 19, 2024

Nov 18, 2024

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 - The Manila Times

Nov 18, 2024

Esperion Highlights New Exploratory Data from CLEAR - GlobeNewswire

Nov 18, 2024

Nov 15, 2024

Esperion Therapeutics (NASDAQ:ESPR) Rating Lowered to Hold at StockNews.com - MarketBeat

Nov 15, 2024

Nov 14, 2024

ESPR: 3 Growth Stocks Under $10 That Analysts Predict Will Skyrocket - StockNews.com

Nov 14, 2024

Two Seas Capital LP Acquires Significant Stake in Esperion Thera - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Nov 08, 2024

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - StockTitan

Nov 08, 2024